Phaseline

Targets › CHEK1

CHEK1 (Serine/threonine-protein kinase Chk1): drug programs, companies and trials

3 programs from 3 companies in 5 trials: 2 Phase 1, 2 Phase 2, 1 Phase 4; Oncology; next expected readout Dec 2026.

Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA. May also negatively regulate cell cycle progression during unperturbed cell cycles. This regulation is achieved by a number of mechanisms that together help to preserve the integrity of the genome. (UniProt, O14757)

Open in Phaseline: the race on CHEK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hospital JP GarrahanABVD
Combination chemotherapy: Doxorubicin (topoisomerase II inhibitor), Bleomycin (DNA damagin
TOP2A, CHEK1Phase 4Pediatric Hodgkin's DiseaseOct 2027
Acrivon TherapeuticsPrexasertib (ACR-368)
Serine/threonine-protein kinase Chk1 inhibitor; Serine/threonine-protein kinase Chk2 inhibitor
CHEK1, CHEK2Phase 2Endometrial Adenocarcinoma; Head and Neck Squamous Cell CarcinomaMay 2027
PharmaEnginePEP07
Selective Chk1 (Checkpoint Kinase 1) inhibitor
CHEK1Phase 1Acute Myeloid Leukemia; Advanced Solid TumorDec 2026

Conditions

Acute Myeloid Leukemia (1) Advanced Solid Tumor (1) Endometrial Adenocarcinoma (1) Head and Neck Squamous Cell Carcinoma (1) Pediatric Hodgkin's Disease (1)

Modalities

small molecule (3)

Companies

PharmaEngine (1) Acrivon Therapeutics (1) Hospital JP Garrahan (1)

Related targets

CHEK2 (1) TOP2A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.